CAPP-seq showed excellent clinical utility in DLBCL with a true-positive recovery rate of 95–99% and a false-negative rate of 1–5% for confirmed mutations, such as EZH2, MYD88, and CD79B [58]. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.